Clinical Dextran Research Articles

Dextran degradation by sonoenzymolysis: Degradation rate, molecular weight, mass fraction, and degradation kinetics

To study dextran degradation by sonoenzymolysis, the degradation rate, the change of molecular weight, the mass fractions of fragments of certain molecular weight, and the degradation kinetics were analyzed and compared with the corresponding parameters under ultrasonic and enzymolysis treatments. The degradation rate improved greatly and the time required to stabilize the rate was shortened compared with ultrasonic treatment, for example, more than 120 min was needed at 4 W/mL for ultrasonic treatment before stabilization with the degradation rate of 77.41%, whereas 80 min was needed for sonoenzymolysis treatment with the degradation rate of 91.44%. A lower molecular weight limit was established (7.15 × 104 Da at 4 W/mL for sonoenzymolysis treatment compared with 19.61 × 104 Da at 4 W/mL for ultrasonic treatment), with decreased time to approach the new limiting molecular weight (80 min compared with more than 120 min). The mass fraction of 104–105 Da fragment increased (61.02% at 4 W/mL for sonoenzymolysis treatment compared with 42.98% at 4 W/mL for ultrasonic treatment) and the dextran degradation kinetics for sonoenzymolysis under lower ultrasonic intensity fitted the Malhotra model well. Sonoenzymolysis treatment at the ultrasonic intensity of 4 W/mL for 80 min resulted in more 104–105 Da fragments in a shorter time. The results indicated that sonoenzymolysis can be applied as an efficient method to obtain clinical dextran.

Purification, Characterization and Degradation Performance of a Novel Dextranase from Penicillium cyclopium CICC-4022.

A novel dextranase was purified from Penicillium cyclopium CICC-4022 by ammonium sulfate fractional precipitation and gel filtration chromatography. The effects of temperature, pH and some metal ions and chemicals on dextranase activity were investigated. Subsequently, the dextranase was used to produce dextran with specific molecular mass. Weight-average molecular mass (Mw) and the ratio of weight-average molecular mass/number-average molecular mass, or polydispersity index (Mw/Mn), of dextran were measured by multiple-angle laser light scattering (MALS) combined with gel permeation chromatography (GPC). The dextranase was purified to 16.09-fold concentration; the recovery rate was 29.17%; and the specific activity reached 350.29 U/mg. Mw of the dextranase was 66 kDa, which is similar to dextranase obtained from other Penicillium species reported previously. The highest activity was observed at 55 °C and a pH of 5.0. This dextranase was identified as an endodextranase, which specifically degraded the α-1,6 glucosidic bonds of dextran. According to metal ion dependency tests, Li+, Na+ and Fe2+ were observed to effectively improve the enzymatic activity. In particular, Li+ could improve the activity to 116.28%. Furthermore, the dextranase was efficient at degrading dextran and the degradation rate can be well controlled by the dextranase activity, substrate concentration and reaction time. Thus, our results demonstrate the high potential of this dextranase from Penicillium cyclopium CICC-4022 as an efficient enzyme to produce specific clinical dextrans.

Purification, characterization, and application of a thermostable dextranase from Talaromyces pinophilus.

Dextranase can hydrolyze dextran to low-molecular-weight polysaccharides, which have important medical applications. In the study, dextranase-producing strains were screened from various soil sources. The strain H6 was identified as Talaromyces pinophilus by a standard ITS rDNA analysis. Crude dextranase was purified by ammonium sulfate fractionation and Sepharose 6B chromatography, which resulted in a 6.69-fold increase in the specific activity and an 11.27% recovery. The enzyme was 58kDa, lower than most dextranase, with an optimum temperature of 45°C and an optimum pH of 6.0, and identified as an endodextranase. It was steady over a pH range from 3.0 to 10.0 and had reasonable thermal stability. The dextranase activity was increased by urea, which enhanced its activity to 115.35% and was conducive to clinical dextran production. Therefore, T. pinophilus H6 dextranase could show its superiority in practical applications.

Clinical dextran purified by fractional ultrafiltration coupled with water washing

Abstract Dextran with extremely narrow molecular weight distribution (MWD) is demanded for clinical use. To elucidate the effect of fractional ultrafiltration on the purification of clinical dextran, a range of ultrafiltration membranes with 100, 30, 5 and 1 kDa molecular weight cut-off (MWCO) were applied. High Performance Gel Permeation Chromatography (HPGPC) analysis indicated that the MWD of ultrafiltrated dextran fractions are wide, with polydispersity index (D) between 2.2 and 5.4, suggesting that the MWD of dextran is hard to be strictly controlled by fractional ultrafitration. However, when coupled with water washing during ultrafiltration process, the homogeneity of dextran was greatly improved. An ultrafiltration fraction of 5–30 kDa (Mw ≈ 35 kDa) with narrow MWD (D = 1.2) was obtained after 5 times of water washing. The results show that fractional ultrafiltration coupled with water washing can be used as a simple and effective method to improve the quality of clinical dextran.

Clinical dextran purified by electric ultrafiltration coupling with solvent crystallization

A new separation method was used to control the molecular weight distribution and improve the quality of clinical dextran. Crystalline solid of dextran was precipitated in the charging basket during the membrane filtration, coupled with solvent crystallization and enhanced by a DC electric field. It was found that the permeate flux of ultrafiltration could be distinctly improved by the applied DC electric field, and the permeate flux of it could be preserved at a high and stable level. Molecular weight distribution of dextran was controlled effectively by ultrafiltration coupled with solvent crystallization. Moreover, organic solvent consumption and processing time can be saved markedly by this new technology.

Anaphylactoid reactions to Dextran 40 and 70: Reports to the United States Food and Drug Administration, 1969 to 2004

Clinical dextrans, such as Dextran 40 and Dextran 70, are associated with anaphylactoid reactions caused by dextran-reactive immunoglobulin G antibodies. When infused immediately before clinical dextrans, dextran 1 significantly reduces the incidence of severe anaphylactoid reactions. The objective of the study was to describe the frequency and characteristics of reports submitted to the United States Food and Drug Administration (FDA) for anaphylaxis or anaphylactoid events after clinical dextran administration. We searched the FDA's Adverse Event Reporting System for reports associated with a clinical dextran and describing anaphylaxis/anaphylactoid reactions. Our case definition for a probable anaphylaxis/anaphylactoid event required signs or symptoms from at least two body systems, with at least one sign or symptom being hypotension, vasodilation, or respiratory difficulty, and onset within 60 minutes. Other reports were considered possible cases if the reporter specifically described the reaction as anaphylaxis or an anaphylactoid reaction. Premier RxMarket Advisor provided estimates of total US hospitalizations with clinical dextran or dextran 1 administration from 2000 to 2004, based on discharge billing data from a sample of US hospitals. The IMS National Sales Perspective provided estimates of total doses of dextrans sold in the United States from 1999 to 2004, based on volumes of dextrans sold in a sample of retail and nonretail outlets. The FDA received 366 clinical dextran adverse event reports from 1969 to 2004, of which 90 (24.6%) were anaphylaxis/anaphylactoid events. The ratio of hospitalizations where clinical dextran was administered to hospitalizations where dextran 1 was administered was 28.4:1. The expected ratio would be 1:1 if all clinical dextran patients had received dextran 1 pretreatment. The ratio of clinical dextran doses sold to dextran 1 doses sold in the United States was 38.6:1. A high proportion of adverse event reports for clinical dextrans described anaphylaxis or anaphylactoid reactions. Hospital discharge and product sales data suggest that dextran 1 has not been used consistently before clinical dextran administration in recent years. To reduce the risk of anaphylactoid reactions, physicians should consider routine administration of dextran 1 before the infusion of a clinical dextran.

Water-soluble and water-insoluble glucans produced by Escherichia coli recombinant dextransucrases from Leuconostoc mesenteroides NRRL B-512F

Two dextransucrase genes, dsrS and dsrT5, from Leuconostoc mesenteroides NRRL B-512F were expressed in Escherichia coli, and recombinant dsrT5 dextransucrase was shown to produce a water-insoluble glucan. In contrast, native dextran from L. mesenteroides B-512F is water-soluble. The water-insoluble glucan was shown by 13C NMR and glycosyl-linkage composition analysis to contain about 50% 6-linked Glc p and 40% 3-linked Glc p. The ‘primitive’ B-512F strain is suggested to have produced water-insoluble glucan containing 3-linked Glc p. The glucans produced by dextransucrases expressed in E. coli contained 4-linked Glc p, as shown by glycosyl-linkage composition analysis. The amount of 4-linked Glc p was increased when the truncated, water-insoluble, glucan-producing dextransucrase, which does not have C-terminal repeating units, was added to the water-soluble, glucan-producing dextransucrase. Trace amounts of 4-linked Glc p were also detected in the dextran obtained from the B-512F culture supernatant, in dextran produced by dextransucrase purified from the B-512F strain culture supernatant, and in clinical dextran. The results of glycosyl-linkage composition analysis suggest that dextransucrases produce 4-linked Glc p as well as 6- and 3-linked Glc p.

Potential of block copolymer- and immuno-conjugates for tumor-targeted delivery of Bowman–Birk soybean proteinase inhibitor

The present work reports the effect of conjugation of the anticarcinogenic and antitumor soybean Bowman–Birk protease inhibitor (BBI) with amphiphilic block copolymer of ethylene oxide and propylene oxide (PEO-PPO) as well as with monoclonal antibody via clinical dextran (D) on tumor-targeted delivery of BBI.

Soybean bowman--birk inhibitor conjugates with clinical dextran. synthesis and antiproteolytic activity.

Conjugates of the classical soybean Bowman-Birk inhibitor (BBI) with clinical dextran were synthesized. Clinical dextran was preliminarily oxidized with periodate to dialdehydedextran (DAD). The effect of the degree of oxidation of DAD on coupling of the inhibitor was evaluated. The binding of the protein was shown to increase with increasing degree of DAD oxidation (5, 10, 20%). Total coupling of the inhibitor occurred when the degree of oxidation of the dextran was 20%. The BBI-DAD (20%) conjugate contained 13% protein with BBI/DAD molar ratio 1 : 1. The conjugates retained the ability to inhibit trypsin (Ki = 0.2-0.3 nM) and alpha-chymotrypsin (Ki = 15-30 nM). Thus, the coupling of BBI with the polymeric carrier caused practically no decrease in the antiproteolytic activity of the inhibitor.

Immunoconjugates of Soybean Bowman-Birk Protease Inhibitor as Targeted Antitumor Polymeric Agents

To enhance the antitumor potential of soybean Bowman-Birk inhibitor (BBI), the conjugate of BBI with an antibody via a macromolecular carrier was prepared. Clinical dextran (D) was used as a biocompatible biodegradable carrier for co-immobilization of BBI and antibody. A model immunoglobulin isolated from sheep serum (slgG), raised against human IgM was utilized to develop the procedure of immunoconjugate synthesis. The molar ratio of the ingredients in the conjugate was the following BBI:D:sIgG=9:1:1. Comparison of the dose response curves for the native sIgG and the BBI-D-sIgG conjugate indicated that sIgG completely retained its specific activity (>90%) after modification with dextran. The determination of the Ki, values for chymotrypsin interaction with the native BBI and the BBI-D-sIgG conjugate indicated high anti-chymotrypsin activity. In the next step, the monoclonal antibody (ICO 25 MAb) against the mucin-like human epithelial membrane antigen was used for conjugation as it is the most universal vector for targeting different agents to human tumors of epithelial origin. The influence of conjugation on the specificity of the Mab reaction with its antigen was studied. The conjugated MAb reacted with tumor cells of different epithelial genesis (breast, lung, gastric, ovarian and uterus tumors), but did not react with tumor cells of non-epithelial origin. It was shown that BBI-D-ICO 25 MAb conjugate has almost the same immunohistochemical activity as non-conjugated MAb. These results demonstrated the feasibility of exploiting the activities of covalently bound BBI and ICO 25 MAb for anticarcinogenic agent targeting.

Optimization of dextran syntesis and acidic hydrolisis by surface response analysis

The influence of some variables in the in vitro synthesis of dextran by dextransucrase from Leusconostoc mesenteroides NRRL B512F, as well as in the acidic hydrolysis of the dextran produced, were studied in order to maximize the production of clinical dextran (dextran 70 and dextran 40). The experiments were conducted using a factorial design and surface response analysis.

Dormant Activity of Cyclodextrin Glucanotransferase on Dextran Afforded the Molecular Changes.

The action of cyclodextrin glucanotransferase (CGTase) on clinical dextran was demonstrated under the reaction conditions of high concentrations of enzyme and substrate. CGTase showed noticeable affinity to Sephadex G-15 gel, and lower but definite hydrolysis reaction of dextran compared with soluble starch was kinetically evaluated. CGTase seemed to cause the molecular disproportionation of dextran, which was suggested by the product analysis after ethanol fractionation of the reaction mixture. The action of the CGTase on dextran reached a maximum at higher pH of 9.5 and temperature of 50°C than with soluble starch as a substrate. Moreover, the addition of surfactant, SDS, or acceptor molecule, such as methyl α-glucoside, greatly affected the CGTase reaction. Changes in molecular weight of the dextran indicated that a clear difference in molecular weight distribution of CGTase-treated dextran had occurred, although the increase in reducing sugar was very small. That is, compared with the dextran (Mw 63, 000), both lower (Mw 10, 000) and higher (more than Mw 500, 000) molecular weight products were obtained. These results strongly suggested evidence for the action of CGTase on α-1, 6-linked dextran.

Further Characterization of Dormant Reaction of Cyclodextrin Glucanotransferase with Dextran and Subsequently Produced Dextran.

Structurally modified dextran was produced by the action of cyclodextrin glucanotransferase (CGTase) on clinical dextran. The dormant activity of CGTase was further confirmed by using the enzyme preparation from a different source. Although an increase in reducing sugar in the reaction mixture was small, a clear difference in the molecular weight distribution of CGTase-treated dextran was observed, as in previous experiments. Therefore the susceptibility of CGTases on dextran was verified with the other origin of CGTase. CGTase-treated dextran showed a higher interaction with Con A and fluorescent reagent, 6-p-toluidinylnaphthalene-2-sulfonate. The susceptibility of CGTasetreated dextran to isoamylase and glucoamylase varied significantly according to the reaction temperatures for the CGTase action. NMR-HMQC and methylation analyses both indicated additional occurrence of α-1, 4-branch points in the dextran molecule, which opposed the knowledge of sole branch point of -1, 3-linkages in the dextran. CGTase action seemed to increase the content of α-1, 4-branch points in the CGTase- treated dextran by introducing the cleaved fragments as the new branch into the back bones of α-1, 6-linkages. These results suggested that CGTasetreated dextran had increasing amounts of α-1, 4-branch points, which caused the structural changes demonstrated by the above analysis.

Affinity chromatography of human anti-dextran antibodies. Isolation of two distinct populations.

Affinity chromatography is a very efficient method for antibody purification. Two affinity chromatography supports were prepared to analyze the specificity of anti-dextran antibodies. Silica beads were grafted with native dextran or with functionalized dextran. The anti-dextran antibodies present in some human sera were analyzed by enzyme-linked immunosorbent assay method. These antibodies play an important role in severe dextran-induced anaphylactic reactions in humans by forming immune complexes with clinical dextran. The results indicated that two distinct populations of anti-dextran antibodies were purified from human serum, using dextran-coated silica beads. Elution from this support with an oligo-dextran of 4000 g/mol allowed the isolation of one population that only recognized native dextran as antigen. Functionalized dextran coated on dextran silica beads led to the purification, with a glycine-HCl buffer, of another subclass of antibodies that recognized substituted dextran derivatives. Furthermore, these antibodies could be useful tools for in vitro and in vivo investigations using dextran derivatives as bio-active polysaccharides.

Mixed culture fermentation for the production of clinical quality dextran with starch and sucrose

Mixed culture fermentations containing a dextranase-producing yeast, Lipomyces starkeyi, and a dextransucrase-producing bacterium, Leuconostoc mesenteroides, produced dextrans of selected size using sucrose and starch. Dextran and starch hydrolyzates, produced by a Lipomyces starkeyi dextranase and amylase, were incorporated into the dextran and formed small size dextran (Mr = 40kDa). The yields of total and clinical dextran in mixed culture fermentation using 12% sucrose and 3% starch were higher, 84 and 79% of theoretical yield, than those using 15% sucrose only, 73 and 69% of theoretical yield, respectively.

Does colloid-induced plasma hyperviscosity in haemodilution jeopardize perfusion and oxygenation of vital organs?

The infusion of dextran solutions is associated with haemodilution and, under some conditions, with a slight increase in plasma viscosity. To clarify the compound effects of simultaneous haemodilution and plasma viscosity increases on macro- and microhaemodynamics, we investigated the changes in arterial perfusion (radiolabelled microspheres, 15 microns ø) and oxygenation (tissue Po2) of vital organs using an animal model of plasma hyperviscosity. In nine splenectomized beagles plasma viscosity was increased step by step from 1.06 (baseline) to 2.14, and 2.99 mPa.s by infusion of small amounts (4% of total blood volume) of an ultra-high-molecular-weight dextran (50% w/v, mw: 500,000). Despite the significant increase in plasma viscosity, cardiac output as well as specific organ blood flows in heart, brain, liver, and muscle rose steadily with each step of viscosity, while the haematocrit declined from 0.31 to 0.24 and 0.20, respectively. Medians of tissue Po2 in liver peaked at a viscosity of 2 mPa.s and returned to baseline values at 3 mPa.s, whereas in non-working skeletal muscle Po2 values were maximal at 3 mPa.s. These results indicate that the impact of plasma viscosity on the rheological properties of whole blood is completely offset by the concomitant reduction of haematocrit. Thus, the comparatively minor changes in plasma viscosity observed after prolonged use of clinical dextrans and other colloids in no way compromise the perfusion and oxygenation of vital organs.

Aggregated form of dextransucrases from Leuconostoc mesenteroides NRRL B-512F and its constitutive mutant.

Purified dextransucrases [EC 2.4.1.5], DSW-D and DSW-G, from Leuconostoc mesenteroides B-512F were obtained from affinity chromatography with DEAE-Sephadex A-50 by elution with clinical dextran and guanidine-HCl, respectively. DSM-G was purified from the B-512F mutant strain SH 3002, which produces dextransucrase constitutively. Although the sugar contents of the purified enzymes were different, their molecular masses by SDS-PAGE were all 170 kDa. DSW-D and DSW-G were highly aggregated and the all the activities were eluted at the void volume (V0) on Sepharose 6B, while the DSM-G was eluted at 1.2 x V0 volume. On rechromatography, DSM-G was separated into three peaks corresponding to the aggregated form, monomeric form, and partially digested form, respectively. The aggregation of Leuconostoc dextransucrase was looser than that of streptococcal glucosyltransferases, but the structures of these enzymes had high homology with each other.

A new process for the production of clinical dextran by mixed-culture fermentation of Lipomyces starkeyi and Leuconostoc mesenteroides

A mixed-culture fermentation system was designed for the production of size-limited dextrans. This process was simpler and more economical than traditional methods. It required the establishment of microbial consortia of Lipomyces starkeyi ATCC 74054 and Leuconostoc mesenteroides ATCC 10830. Controlling initial conditions, growth, and enzyme production by both organisms controlled the product size. In this process, both strains were grown separately and then mixed. Dextran fermentation was then allowed to proceed. At the desired time (and molecular size), the fermentation was harvested. The optimum pH and temperature for production of clinical dextran (75,000 MW) were 5.2 (±0.1) and 28 (±0.5) °C, respectively. Varying the ratio of L. mesenteroides to L. starkeyi in the inoculum did not significantly affect either the final cell ratios or dextran production.

Functional changes of dextran-modified alkaline proteinase from alkalophilic Bacillus sp

A serine alkaline proteinase (EC 3.4.21.62) from Bacillus sp. (ALPase I) was modified with the 2,4-dialdehyde derivative of clinical dextran (dialdehyde dextran). The modified preparation was purified using an ion-exchange column and gel filtration. The modified enzyme contained 75% carbohydrate by weight. The isoelectric point (pI) of ALPase I was converted from 8.2 to approximately 5.0 by this modification. The specific activity of the dextran-modified ALPase I was 56% of that of the native enzyme when milk casein was used as a substrate. It also had some superior characteristics: the thermostability of the modified enzyme at pH 10.0 was about 10–15°C higher than that of control. In organic solvents such as n-hexane, benzene, and toluene, the hydrolysis reaction of the modified ALPase I for the fluorogenic substrate, succinyl- l-alanyl- l-alanyl- l-prolyl- l-phenylalanyl-4- methylcoumaryl-7-amide (Suc-Ala-Ala-Pro-Phe-MCA), was several times higher than that of the native. This modification greatly improved the stability of ALPase I against nonionic and anionic surfactants. After exposure to lauryl benzene sulfonate and sodium lauryl sulfonate the modified enzyme retained over 95 and 90% of its activity, respectively, but the native enzyme lost its activity. We conclude that modification of serine proteinases with dialdehyde-dextran might be a useful method for improving enzyme character for enzyme technology.

Analytical gel filtration of dextran for study of the glomerular barrier function

Analytical gel filtration was used for the study of molecular size distribution of clinical dextran in serum and urine for the purpose of evaluations of changes in the human glomerular barrier function. The column was calibrated in terms of solute size using a simple and accurate technique recently described. Only one sample of a dextran possessing a broad molecular mass distribution was necessary for the calibration procedure and the calculations were performed using an ordinary spreadsheet. The accuracy of the calibration, as evaluated by protein samples, is better than 95%. The simplicity makes the method suitable for use in laboratories not normally specializing in analytical gel filtration. Calibration in terms of size is preferably done with respect to viscosity radius to obtain relevant information about the permeability of dextran into porous membranes.